Pure Global
NCT05290662

Registry of Patients Having Received oNKord®

A Prospective Multicenter Observational Study to Assess Long-term Outcome of Participants Who Have Received oNKord®
Glycostem Therapeutics BV·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
AML
Drug/Device/Intervention
oNKord®
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Glycostem Therapeutics BV
Location
Hannover,Basel, Germany,Switzerland
Timeline & enrollment
Phase
N/A
Start date
Jun 14, 2022
End date
Mar 01, 2028
Enrollment
50 participants
Primary outcome

Incidence of SAEs related to oNKord® over time,Incidence of SAEs related to Cyclophosphamide-Fludarabine over time,Long-term follow-up on survival,Long-term follow-up on disease status,Long-term follow-up on cancer-related treatments

Summary

ReKORD is an observational study (Registry) enrolling participants who have received at least
 one dose of oNKord® (allogeneic ex vivo-generated Natural Killer [NK] cells from CD34+
 umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple
 previous clinical trials of oNKord® can be enrolled in this Registry.

ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05290662
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05290662 through Pure Global AI's free database. This phase not specified trial is sponsored by Glycostem Therapeutics BV and is currently Recruiting. The study focuses on AML. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.